Cancer ResearchTrial Tests Whether Stopping Immunotherapy Early Harms NSCLC Patients Who Respond
This Phase 2 trial from Institut Bergonié explored a pressing clinical question in lung cancer care: once a patient responds to immune checkpoint inhibitor therapy within 6 to 12 months, is it safe to stop treatment? Continuing immunotherapy indefinitely carries costs, side effects, and quality-of-life burdens, yet stopping too early risks disease relapse. The study randomized NSCLC patients who achieved a meaningful response to either continue or discontinue their PD-1 or PD-L1 blocking therapy. Unfortunately, the trial was terminated early with only 8 participants enrolled, far below the target needed for meaningful statistical conclusions. While no efficacy data are available, the research question remains critically important for oncology practice and patient wellbeing. Larger, better-powered studies are urgently needed to answer this unresolved question.
